



IpA

IMMUNOPRECISE ANTIBODIES

Toward full *in silico* drug discovery

Conquering the impossible

March 2023 | NASDAQ:IPA

ENGINEERED for the biotherapeutic RACE

Disclosures

Disclaimer

This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of ImmunoPrecise Antibodies Ltd. (the “Company”) securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilities or of the Company’s securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors & does not take into account the investment objectives, financial situation or needs of any investor. All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate. The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein. These projections should not be considered a representation of the Company’s potential cash generation performance in any way.

Forward Looking Statements

This presentation includes forward-looking statements to provide prospective investors with information pertaining to the Company’s long-term business objective. Forward-looking statements often, but not always, are identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “targeting” and “intend” and statements that an event or result “may”, “will”, “should”, “could”, or “might” occur or be achieved and other similar expressions.

Forward-looking statements are not statements of historical fact or assurances of future performance. They are based on the current beliefs, expectations & assumptions of the Company’s management about the Company’s business, planned acquisitions, future plans, anticipated events & other future conditions. All forward-looking statements attributable to the Company or persons acting on its behalf apply only as of the date of this document & are expressly qualified in their entirety by the cautionary statements included in this presentation.

The forward-looking statements that are contained in this presentation involve a number of risks and uncertainties and are based on certain assumptions, including: the progress, timing and costs related to the execution of the Company’s business plan and strategy; estimates and projections regarding the industry in which the Company operates; the future success of research and development activities; the absence of material changes in general business and economic conditions; estimates regarding the future financing and capital requirements; and the absence of adverse changes in relevant laws and regulations. As a consequence, actual results might differ materially from results forecast or suggested in these forward-looking statements. Further information on risks and uncertainties may be found in the Company’s Management Discussion & Analysis which may be obtained from SEDAR at www.sedar.com and SEC at www.sec.gov.

Furthermore, forward-looking statements contained herein are made as of the date of this MD&A and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

About ImmunoPrecise

IPA (ImmunoPrecise Antibodies) is revolutionizing the antibody discovery industry with its cutting-edge technologies and AI-driven platform, LENS^{ai}.

Founded in 1983

Our mission:

is to **reduce the risk, time, and cost associated with antibody discovery**, ultimately leading to safer and more effective therapies that reach patients faster and provide unparalleled value for partners and investors.



IpA



Invested in transformation and the future

Vision

In 2018, the company began an ambitious transformation, including strategic investments into technology-focused R&D and acquisitions

One core focus – developing clinically-relevant antibodies while obtaining massive amounts of high-quality data.

Antibody Development + AI Technology

Example: Best-in-class high-throughput single memory B cell sorting used to directly extract the DNA sequences of antibodies with KNOWN FUNCTIONS, representing potentially life-saving therapies.

LENS^{ai} from BioStrand (an IPA subsidiary) is the world's only revolutionary AI algorithm that analyzes multi-omics data simultaneously at unlimited scale.

Our technologies are game-changers.

Industry-leading wet-lab tech provides clinically validated, large-scale annotated DNA sequences with functional data, analyzed in a scalable cloud repository.



Our human libraries contain billions of antibody sequences that can be easily and rapidly screened, making them a go-to resource massive data analysis.

Clients: 80% of top 20 pharma

Robust end-to-end discovery, development and manufacturing services with individualized access to best-in-class AI algorithms.

#1 ranked CRO

Acclaimed by independent company Roots Analysis.¹

A paradigm shift

LENS^{ai} – Unlocking endless possibilities

Unequalled software in attaining *in silico* outputs

- Analyze biological data from any perspective.
- Reduces risk, time, and cost.

Allows instant access to data across the entire biosphere.



Wide range of inputs and formats: multi-omic sequences, peer-reviewed literature, articles, clinical trial datasets, patents.



IpA





The *Google* *of Genomics*

Disruptive AI-driven biotherapeutic discovery potential

- Accelerate discovery
- Infinite scale with massive multi-source inputs
- Deliver rapid insight and critical analysis
- Discover hidden knowledge
- Benchmark lead candidates
- Build a knowledge base

The Opportunity

Creating efficiencies for pharmaceutical discovery




Analyzing the immense

Managing vast data extends into protein complexity

- Protein diversity renders standard AI programming ineffective.
- Therapeutic discovery is an intricate combinatorial challenge
- $\sim 20^{62}$ mAbCDR variants, which is more than the...
 $\sim 10^{80}$ *atoms in the universe*
- Simpler targets are spoken for. Market is moving towards complex targets such as GPCRs, ion channels, microbiome, etc.


Small Molecule:

Aspirin
-21 Atoms



Protein Therapeutic:

Monoclonal Antibodies
-25,000 Atoms



The HYFTs – our secret weapon

Smarter by the second



Amplifying biotherapeutic intelligence

Cyclic feedback loop continuously enriched by massive genetic data sources

LENS^{ai} is powered by our proprietary HYFT technology

Cutting-edge algorithm identifies sequence and structural patterns in biosphere.

- Like Google's index, the HYFT Index is in a perpetual state of motion.
- HYFTs build data harmonization.
- Potential for expedited commercial products, leading to unique patent opportunities and extended commercial revenues.





LENS^{ai} + HYFTs – The key to a new era in discovery.



Unparalleled massive multi-omics biotherapeutic data inputs

The only truly unified single-platform for drug discovery.


Allowing unprecedented insight, speed and efficiency.

- Real-time ability to search and analyze biological data from any perspective.
- Data readily available to support every step of development.



Powering the intersection of biotech discovery, biotherapeutics and AI

Quickly identify potential candidates. This new way of thinking has the potential to accelerate the discovery of novel therapeutics as we know it.



Knowledge graph:
25 billion relationships
is foundation for
de novo discovery.

Represents months
to years' worth
of traditional research.

Leveraging multi-omics sequences, clinical trial datasets, patents, peer-reviewed literature articles, and more.



Setting the pace

The biotherapeutic race is undergoing a fundamental transformation.

We are at the forefront of accelerating next-gen novel drug discovery.



Driven by an unparalleled intelligence combination

Unlimited scalability, real-time analytics, continuous learning curated from massive amounts of quality genetic data.



Superior research data and storage

Knowledge base developed by integrating vast multi-omics data and supported by #1 ranked¹ CRO wet lab.



The only truly unified single-platform available —

Real-time access — reducing the time, risk and costs of drug development.

HUB of Biotherapeutic Intelligence™



IpA

IMMUNOPRECISE ANTIBODIES

Thank you

Together, let's revolutionize the world
of therapeutics.

HUB of Biotherapeutic Intelligence™
<http://www.ipatherapeutics.com/> | **NASDAQ:IPA**

ENGINEERED for the human RACE